Epilepsy Drugs Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment, Distribution Channel, and Geography
간질 치료제 시장 규모는 2022년에 77억 6,800만 달러로 평가되었고, 2030년에는 107억 500만 달러에 이를 것으로 예측되며, 2022-2030년간 CAGR은 4.1%로 예측됩니다. 간질 치료제 시장의 성장은 주로 간질의 유병률 증가와 노인 증가로 이어집니다.
간질은 발작을 일으키는 신경 질환으로 세계적으로 수백만 명이 앓고 있습니다. 간질 치료제는 항 간질 약물(AED)로도 알려져 있으며 간질 환자의 발작을 더 잘 관리하는 데 도움이되므로 간질 치료에 일반적으로 사용됩니다. 약물 저항성 간질 환자 중 일부는 수술 및 발작 관리에 도움이 되는 뇌내 임베디드 장치와 같은 다른 치료법을 선택하는 사람들도 있습니다.
간질 치료제 시장의 성장 기회를 창출하는 특허 부족에 가까운 여러 간질 치료제
간질 치료제 시장에서는 향후 몇 년동안 많은 특허가 부족할 것으로 예상됩니다. 의료비 절감으로 인해 제네릭 의약품의 보급이 진행될 가능성이 높습니다. 이로 인해 다른 시장 기업에게도 새로운 비즈니스 기회가 생길 것입니다.
치료별 통찰
간질 치료제 시장은 치료별로 1세대 항간질제, 2세대 항간질제, 3세대 항간질제로 구분됩니다. 2022년에는 2세대 항간질약 부문이 최대 시장 점유율을 차지하고, 2022-2030년에는 3세대 항간질약이 가장 빠른 CAGR을 기록할 것으로 추정됩니다. 2세대 AED에는 페르바메이트, 가바펜틴, 라모트리긴, 레베티라세탐, 옥스카르바제핀, 프레가발린, 루피나미드, 설피펜톨, 티아가빈, 토피레이트, 토피라마트, 비가바트린, 조니사미드가 포함됩니다. 북미와 유럽에서는 ZNS도 2세대 약물로 간주됩니다. 2세대 AED는 1세대 AED에 비해 고가인 것이 처방전에 대한 기재를 제한하는 큰 요인이 되고 있습니다. 2세대 AED는 1세대에 비해 부작용 프로파일이 좋고 최기형성 위험도 낮습니다. 많은 1세대와 일부 2세대(AED)는 유도제 작용의 감소와 함께 시토크롬 p450 효소가 표적으로 하는 다양한 기질의 대사를 증가시키는 효소 유도라는 공통된 특징을 가지고 있습니다.
유통 채널별 통찰
간질 치료제 시장은 유통 채널별로 병원 약국, 소매 약국 등으로 구분됩니다. 2022년에는 병원 약국 부문이 가장 큰 시장 점유율을 차지하고 2022-2030년에는 소매 약국 부문이 가장 빠른 CAGR을 기록할 것으로 예측됩니다. 병원 약국은 다양한 기업에서 의약품을 구입하여 외래 또는 입원 환자의 치료를 위해 병원에 공급합니다. 병원 약국은 일반적으로 심장병학, 신경학, 비뇨기학, 병리학, 혈액학, 피부과학에 적용되는 치료제와 중증 치료제를 제공합니다. 병원 약국은 모든 국가의 건강 관리 시스템에 필수적인 존재입니다. 이 약국에서는 간질 치료제의 재고를 관리하고 환자가 즉시 사용할 수 있도록합니다. 따라서 병원 약국은 간질 치료제 시장의 상당한 규모를 차지합니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 간질 치료제의 전망
제5장 간질 치료제 시장 : 주요 산업 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 향후의 동향
- 영향 분석
제6장 간질 치료제 : 세계 시장 분석
제7장 간질 치료제 세계 시장 - 치료별 수익과 예측(-2030년)
- 간질 치료제 시장의 수익 점유율, 치료별(2022년 및 2030년)(%)
- 제1세대 항간질약
- 제2세대 항간질약
- 제3세대 항간질약
제8장 간질 치료제 세계 시장 - 유통 채널별 수익과 예측(-2030년)
- 간질 치료제 시장의 수익 점유율, 유통 채널별(2022년 및 2030년)(%)
- 병원 약국
- 소매 약국 점포
- 기타
제9장 간질 치료제 시장 - 지역별 수익과 예측(-2030년)
- 북미
- 유럽
- 아시아태평양
- 중동 및 아프리카
- 중남미
제10장 간질 치료제 시장 - 업계 정세
- 간질 치료제 시장의 성장 전략
- 무기적 성장 전략
- 유기적 성장 전략
제11장 기업 프로파일
- UCB SA
- Novartis AG
- Pfizer Inc
- GSK Plc
- Abbott Laboratories
- Sanofi SA
- Sumitomo Pharma America Inc.
- Teva Pharmaceutical Industries Ltd
- Catalyst Pharmaceuticals Inc
- Alkem Laboratories Ltd
제12장 부록
JHS
The epilepsy drugs market size was valued at US$ 7.768 billion in 2022 and is projected to reach US$ 10.705 billion by 2030; it is estimated to register a CAGR of 4.1% from 2022 to 2030. The epilepsy drugs market growth is primarily driven by the increasing prevalence of epilepsy and an increasing number of elderly people.
Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.
Several Epilepsy Drugs Nearing Patent Expiration Creating Opportunities for Epilepsy Drugs Market Growth
Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.
Company Patent Patent Expiration Date Ingredient Treatment
Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy
GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy
Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures
SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies
SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy
Treatment-Based Insights
The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022-2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.
Distribution Channel-Based Insights
The epilepsy drugs market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022-2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drug market.
A few of the major primary and secondary sources referred to while preparing the report on the epilepsy drugs market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Investor presentations and Annual Reports of Market players.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the epilepsy drugs market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global epilepsy drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the epilepsy drugs market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Epilepsy Drugs Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 Global PEST Analysis
5. Epilepsy Drugs Market - Key Industry Dynamics
- 5.1 Market Drivers
- 5.1.1 Growing Prevalence of Epilepsy
- 5.1.2 Increasing Number of Elderly People
- 5.2 Market Restraints
- 5.2.1 Recall of Therapeutic Products
- 5.3 Market Opportunities
- 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
- 5.4 Future Trends
- 5.4.1 Increasing Product Approvals
- 5.5 Impact Analysis
6. Epilepsy Drugs Market - Global Market Analysis
- 6.1 Epilepsy Drugs Revenue (US$ Mn), 2022 - 2030
7. Global Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment
- 7.1 Overview
- 7.2 Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
- 7.3 First Generation Antiepileptics
- 7.3.1 Overview
- 7.3.2 First Generation Antiepileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Second Generation Anti-epileptics
- 7.4.1 Overview
- 7.4.2 Second Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5 Third Generation Anti-epileptics
- 7.5.1 Overview
- 7.5.2 Third Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8. Global Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel
- 8.1 Overview
- 8.2 Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
- 8.3 Hospital Pharmacy
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 8.4 Retail Pharmacy Stores
- 8.4.1 Overview
- 8.4.2 Retail Pharmacy Stores: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9. Epilepsy Drugs Market - Revenue and Forecast to 2030 - Geographic Analysis
- 9.1 North America: Epilepsy Drugs Market
- 9.1.1 Overview
- 9.1.2 North America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.3 North America: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.1.4 North America: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.1.4.1 US: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.4.1.1 Overview
- 9.1.4.1.2 US: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.4.1.3 US: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.1.4.1.4 US: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.1.4.2 Canada: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.4.2.1 Overview
- 9.1.4.2.2 Canada: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.4.2.3 Canada: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.1.4.2.4 Canada: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.1.4.3 Mexico: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.4.3.1 Overview
- 9.1.4.3.2 Mexico: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.4.3.3 Mexico: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.1.4.3.4 Mexico: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.2 Europe: Epilepsy Drugs Market
- 9.2.1 Overview
- 9.2.2 Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.3 Europe: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.2.4 Europe: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.2.5 Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
- 9.2.5.1 Germany: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.1.1 Overview
- 9.2.5.1.2 Germany: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.1.3 Germany: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.2.5.1.4 Germany: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.2.5.2 France: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.2.1 Overview
- 9.2.5.2.2 France: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.2.3 France: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.2.5.2.4 France: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.2.5.3 UK: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.3.1 Overview
- 9.2.5.3.2 UK: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.3.3 UK: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.2.5.3.4 UK: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.2.5.4 Italy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.4.1 Overview
- 9.2.5.4.2 Italy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.4.3 Italy: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.2.5.4.4 Italy: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.2.5.5 Spain: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.5.1 Overview
- 9.2.5.5.2 Spain: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.5.3 Spain: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.2.5.5.4 Spain: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.2.5.6 Rest of Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.6.1 Overview
- 9.2.5.6.2 Rest of Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.5.6.3 Rest of Europe: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.2.5.6.4 Rest of Europe: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.3 Asia Pacific: Epilepsy Drugs Market
- 9.3.1 Overview
- 9.3.2 Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.3 Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.3.4 Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.3.5 Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
- 9.3.5.1 China: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.1.1 Overview
- 9.3.5.1.2 China: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.1.3 China: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.3.5.1.4 China: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.3.5.2 Japan: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.2.1 Overview
- 9.3.5.2.2 Japan: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.2.3 Japan: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.3.5.2.4 Japan: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.3.5.3 India: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.3.1 Overview
- 9.3.5.3.2 India: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.3.3 India: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.3.5.3.4 India: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.3.5.4 Australia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.4.1 Overview
- 9.3.5.4.2 Australia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.4.3 Australia: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.3.5.4.4 Australia: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.3.5.5 South Korea: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.5.1 Overview
- 9.3.5.5.2 South Korea: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.5.3 South Korea: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.3.5.5.4 South Korea: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.3.5.6 Rest of Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.6.1 Overview
- 9.3.5.6.2 Rest of Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.5.6.3 Rest of Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.3.5.6.4 Rest of Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.4 Middle East & Africa Epilepsy Drugs Market
- 9.4.1 Overview
- 9.4.2 Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.3 Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.4.4 Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.4.4.1 South Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.4.1.1 Overview
- 9.4.4.1.2 South Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.4.1.3 South Africa: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.4.4.1.4 South Africa: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.4.4.2 Saudi Arabia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.4.2.1 Overview
- 9.4.4.2.2 Saudi Arabia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.4.2.3 Saudi Arabia: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.4.4.2.4 Saudi Arabia: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.4.4.3 UAE: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.4.3.1 Overview
- 9.4.4.3.2 UAE: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.4.3.3 UAE: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.4.4.3.4 UAE: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.4.4.1 Overview
- 9.4.4.4.2 Rest of Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.4.4.3 Rest of Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.4.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.5 South & Central America: Epilepsy Drugs Market
- 9.5.1 Overview
- 9.5.2 South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5.3 South & Central America: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.5.4 South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.5.5 South & Central America: Epilepsy Drugs Market Share by Country - 2022 & 2030, (%)
- 9.5.5.1 Brazil: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5.5.1.1 Overview
- 9.5.5.1.2 Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
- 9.5.5.1.3 Brazil: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.5.5.1.4 Brazil: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.5.5.2 Argentina: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5.5.2.1 Overview
- 9.5.5.2.2 Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
- 9.5.5.2.3 Argentina: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.5.5.2.4 Argentina: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.5.5.3 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5.5.3.1 Overview
- 9.5.5.3.2 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5.5.3.3 Rest of South & Central America: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.5.5.3.4 Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Epilepsy Drugs Market-Industry Landscape
- 10.1 Overview
- 10.2 Growth Strategies in the Epilepsy Drugs Market
- 10.3 Inorganic Growth Strategies
- 10.4 Organic Growth Strategies
11. Company Profiles
- 11.1 UCB SA
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
- 11.2 Novartis AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
- 11.3 Pfizer Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
- 11.4 GSK Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
- 11.5 Abbott Laboratories
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
- 11.6 Sanofi SA
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
- 11.7 Sumitomo Pharma America Inc.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
- 11.8 Teva Pharmaceutical Industries Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
- 11.9 Catalyst Pharmaceuticals Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
- 11.10 Alkem Laboratories Ltd
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments
12. Appendix
- 12.1 About Us
- 12.2 Glossary of Terms
